Not Yet RecruitingPhase 1/2

Mesenchymal Stem Cells for Chronic Kidney Diseases

32 participantsStarted 2026-01-01

Plain-language summary

This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Agreement to participate in the trial and provision of signed written informed consent * Pathological diagnosis of diabetic nephropathy or hypertensive renal damage * 15 ≤ eGFR \< 60 mL/min/1.73m², UACR \> 300 mg/g * Age ≥ 18 years Exclusion Criteria: * Extremely severe anemia (hemoglobin \< 30 g/L) * Received blood product transfusion therapy within 1 month * Autosomal dominant or recessive polycystic kidney disease (ADPKD) * History of kidney transplant or other solid organ transplant * Active systemic or localized infection (e.g., pneumonia, osteomyelitis) * Allergy to stem cells themselves or stem cell-related culture medium * History of allergic reaction to cell products (e.g., blood transfusion, platelets) * History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis) * History of malignancy or current malignant disease * Elevated tumor markers (AFP, CEA, CA199, CA125, etc.) * Pregnant women or women with plans for pregnancy within 3 months after MSC therapy * Participation in drug-related clinical trials within the past 2 months * Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Primary Outcome Measure

Timeframe: From enrollment to the end of treatment at 12 months

Trial details

NCT IDNCT07240987

SponsorThe First Affiliated Hospital of Air Force Medicial University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-31

View on ClinicalTrials.gov More Kidney Disease, Chronic trials